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Alcohol exposure disrupts mu opioid receptor-
mediated long-term depression at insular cortex
inputs to dorsolateral striatum
Braulio Muñoz1, Brandon M. Fritz1, Fuqin Yin1 & Brady K. Atwood1,2,3
Drugs of abuse, including alcohol, ablate the expression of speciﬁc forms of long-term
synaptic depression (LTD) at glutamatergic synapses in dorsal striatum (DS), a brain region
involved in goal-directed and habitual behaviors. This loss of LTD is associated with altered
DS-dependent behavior. Given the role of the µ-opioid receptor (MOR) in behavioral
responding for alcohol, we explored the impact of alcohol on various forms of MOR-mediated
synaptic depression that we ﬁnd are differentially expressed at speciﬁc DS synapses. Cor-
ticostriatal MOR-mediated LTD (mOP-LTD) in the dorsolateral striatum occurs exclusively at
inputs from anterior insular cortex and is selectively disrupted by in vivo alcohol exposure.
Alcohol has no effect on corticostriatal mOP-LTD in dorsomedial striatum, thalamostriatal
MOR-mediated short-term depression, or mOP-LTD of cholinergic interneuron-driven glu-
tamate release. Disrupted mOP-LTD at anterior insular cortex–dorsolateral striatum synapses
may therefore be a key mechanism of alcohol-induced neuroadaptations involved in the
development of alcohol use disorders.
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Many drugs of abuse, including opioids and alcohol,impact neurotransmission in the dorsal striatum (DS)1.For example, we previously demonstrated that the
heavily abused prescription opioid, oxycodone, ablates speciﬁc
forms of synaptic plasticity in mouse DS2. While abuse of opioid
analgesics is a growing and alarming epidemic3, alcohol use
disorders (AUDs) are also a signiﬁcant source of great medical,
social, and economic burdens throughout the world4. The pro-
gression of AUDs involves increasingly heightened activity within
the basal ganglia in response to alcohol cues5. The DS is the
primary input nucleus of the basal ganglia. Functionally, the DS
can be divided into the dorsomedial striatum (DMS), which plays
an important role in goal-directed learning, and the dorsolateral
striatum (DLS), which regulates habit formation6,7. The specia-
lized nature of these dorsal striatal subregions also extends to
goal-directed and habitual ethanol (EtOH) seeking7. Both sub-
regions are composed of ~95% GABAergic medium spiny pro-
jection neurons (MSNs) in rodents8. MSN activity is driven by
glutamatergic input from three distinct sources: cerebral cortex,
thalamic nuclei, and cholinergic interneurons (CINs) that can co-
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Fig. 1 MOR activation produces LTD of excitatory transmission in the dorsal striatum. a Schematic ﬁgure of coronal brain slice showing the recording of
EPSCs evoked by focal electric stimulation in the dorsolateral striatum (DLS) of C57BL/6J mice. b Representative electrically evoked synaptic traces at
baseline and after DAMGO (0.3 μM, 5min) application. c DAMGO induced mOP-LTD of eEPSC amplitude in DLS MSNs of C57BL/6J mice (n= 7 slices
from 4 mice). d The presence of mOP-LTD is not related to alterations in series resistance. e Schematic ﬁgure of coronal brain slice showing the recording
of eEPSCs by focal electric stimulation in the dorsomedial striatum (DMS). f Representative electrically evoked synaptic traces before and after DAMGO
(0.3 μM, 5min) application. g The activation of MOR by DAMGO induced LTD of eEPSC amplitude in DMS MSNs of C57BL/6J (n= 6 from 2 mice). h The
series resistance was stable during DMS recordings. Data represent mean ± SEM
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release glutamate9–11. Drugs of abuse that affect glutamatergic
input on to MSNs produce alterations in dorsal striatal-
dependent behavior12–17.
The opioid system is robustly expressed throughout the stria-
tum18 and is targeted by one of the few approved pharmacolo-
gical interventions for AUDs, the opioid receptor antagonist
naltrexone, which acts most selectively at µ-opioid receptors
(MORs)19. MORs are key to modulating the rewarding effects of
various drugs of abuse including alcohol18. The opioid system
promotes synaptic plasticity in many brain regions20–26, includ-
ing the DS, where MOR activation induces static long-term
depression (mOP-LTD) of glutamate release in both the DLS and
DMS2,27. Interestingly, mOP-LTD is disrupted in the DLS by a
single in vivo exposure to oxycodone, an effect persisting for
3 days post exposure2. In vivo EtOH exposure ablates endo-
cannabinoid LTD (eCB-LTD), another form of LTD in the
DS13,15,17. We previously showed that mOP-LTD and eCB-LTD
interact and an oxycodone injection also interferes with eCB-
LTD2. We hypothesized that EtOH would also disrupt mOP-
LTD. However, it is unclear which glutamatergic input(s) express
mOP-LTD. Our previous work demonstrated that inputs from
motor cortex exhibit delta opioid receptor-mediated LTD (dOP-
LTD), but are unaffected by MOR activation. Conversely, thala-
mostriatal glutamate release was strongly, but transiently, inhib-
ited by MOR activation, but insensitive to activation of the delta
receptor2. We therefore hypothesized that mOP-LTD is expressed
at other cortical inputs to DS. In addition, EtOH effects on input
and region speciﬁcity of MOR plasticity have yet to be addressed.
In the current study, we use a combination of mouse brain slice
electrophysiology, in vivo EtOH exposure, optogenetics, and
conditional MOR knockout mice to probe MOR-mediated
synaptic plasticity at the three sources of glutamatergic input to
MSNs (cortical, thalamic, and CIN inputs) in the DS. Using these
tools, we demonstrate that in vivo EtOH exposure persistently
and speciﬁcally interferes with corticostriatal mOP-LTD exclu-
sively within the DLS. Furthermore, we ﬁnd that thalamostriatal
MOR-mediated short-term depression and a novel form of
plasticity, mOP-LTD of glutamate release from CINs, are unaf-
fected by EtOH exposure. Finally, we identify the anterior insular
cortex as the speciﬁc cortical input region that expresses alcohol-
sensitive mOP-LTD in the DLS.
Results
MOR activation produces excitatory LTD in the DS. To con-
ﬁrm previously established static mOP-LTD in the DS2, elec-
trically evoked excitatory postsynaptic currents (eEPSCs) were
recorded before (10 min) and after a 5 min application of the
MOR agonist [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin
(DAMGO, 0.3 μM). Consistent with our previous observations2,
this brief application of DAMGO produced a persistent decrease
in eEPSC amplitude in dorsal striatal MSNs (Fig. 1,
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Fig. 2 mOP-LTD occurs at corticostriatal but not thalamostriatal inputs. a Schematic of coronal brain slice showing the recording of oEPSCs by wide-ﬁeld
light stimulation (470 nm) in DLS of Ai32-Emx1Cre+ mice. mOP-LTD of cortical inputs occurs after the application of DAMGO (0.3 μM, 5min) (n= 8
from 7 mice). b Schematic of coronal brain slice showing the recording of oEPSCs in DMS. mOP-LTD occurs in cortical inputs to DMS MSNs (n= 9 from 5
mice). c, d Activation of MORs (DAMGO 0.3 μM, 5min) at thalamic inputs in Ai32-Vglut2Cre+ mice produces mOP-STD in the DLS (n= 7 from 3 mice)
and the DMS (n= 6 from 2 mice). Data represent mean ± SEM. Traces in a, b represent average baseline oEPSCs and post-DAMGO oEPSCs. Traces in c, d
represent average baseline oEPSC, average peak DAMGO inhibition oEPSC (14–19 min), and ﬁnal 10min after DAMGO average oEPSC
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Supplementary Fig. 1a, b). This LTD is stable (≥40 min post
DAMGO) and observed in both DLS (average EPSC amplitude
for ﬁnal 10 min of recording relative to 10 min baseline average:
74.5 ± 3.3%; Fig. 1b, c) and DMS (88.8 ± 3.2%; Fig. 1f, g). The
observed glutamatergic depression was not a result of an increase
in series resistance (Fig. 1d, h). These data demonstrate the
presence of LTD mediated by the activation of striatal MORs in
mouse DMS and DLS.
mOP-LTD occurs at cortico but not thalamostriatal synapses.
To probe the glutamatergic circuits involved in mOP-LTD within
the DS, we used transgenic mice and optogenetic tools to selec-
tively activate cortical (Ai32-Emx1Cre+ mice) and thalamic
(Ai32-Vglut2Cre+ mice) inputs onto dorsal striatal MSNs28–31.
Interestingly, we found that when performing optical stimulation
of cortical inputs, DAMGO induced robust mOP-LTD of opti-
cally evoked EPSCs (oEPSCs) in the DLS (59.1 ± 5.2%; Fig. 2a,
Supplementary Fig. 1c) and a weaker mOP-LTD in the DMS
(73.9 ± 3.3%; Fig. 2b, Supplementary Fig. 1d) of Ai32-Emx1Cre+
mice. However, using thalamic stimulation, DAMGO produced a
labile plasticity at glutamatergic synapses that we term MOR-
mediated short-term depression (mOP-STD). mOP-STD reached
maximal suppression shortly after the end of DAMGO applica-
tion (DLS: 79.5 ± 9.1%, Fig. 2c; DMS: 69.0 ± 7.7%, Fig. 2d) that
returned to baseline levels in the DLS (100.6 ± 9.6%; Fig. 2c,
Supplementary Fig. 1e) and DMS (104.9 ± 9.9%; Fig. 2d, Sup-
plementary Fig. 1f). Thus, MOR activation at cortical afferent
terminals is sufﬁcient to induce glutamatergic LTD. Conversely,
MORs at thalamostriatal synapses are responsible for glutama-
tergic STD. These data demonstrate synapse speciﬁcity of MOR
effects on neuroplasticity within the DS.
In vivo exposure to EtOH reduces mOP-LTD only in DLS. We
tested whether in vivo administration of EtOH (2.0 g/kg, intra-
peritoneal (i.p.)) inﬂuenced the expression of mOP-LTD in the
DS. Mice injected with saline (i.p.) 24 h before being killed
showed normal LTD in both the DLS (76.1 ± 1.8%; Fig. 3b, c) and
DMS (80.6 ± 3.0%; Fig. 3e, f) following bath application of
DAMGO. In mice injected with EtOH 24 h before harvesting
tissue, DAMGO-induced mOP-LTD was blunted in the DLS
(90.2 ± 3.4%; Fig. 3a–c). However, EtOH pre-exposure did not
inﬂuence mOP-LTD in the DMS (82.9 ± 2.3%; Fig. 3d–f). In sum,
the data indicate that a single in vivo EtOH exposure is able to
disrupt mOP-LTD, but this effect is regionally speciﬁc to the DLS.
EtOH drinking disrupts mOP-LTD for several days in DLS.
Given that contingent and non-contingent alcohol exposure has
been observed to differentially affect neurophysiology and neu-
rochemistry in some cases32–34, we compared the effects of the
single exposure of experimenter-administered EtOH on mOP-
LTD to voluntary binge drinking. Using the ‘drinking-in-the-
dark’ (DID) mouse binge-like drinking paradigm35, we compared
the effects of DAMGO treatment on eEPSCs in mice that had
consumed EtOH with those that had consumed sucrose via DID
(Fig. 4a–c). Given that sugar also activates neural reward
mechanisms and circuitry36, sucrose consumption was used as a
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Fig. 3 A single in vivo exposure to EtOH prevents induction of mOP-LTD speciﬁcally in DLS. C57BL/6J mice were injected (intraperitoneal) with saline or
EtOH (2 g/kg). At 24 h after this injection, eEPSCs in MSNs from the DLS and the DMS were recorded. a Representative electrically evoked synaptic traces
from the DLS before and after DAMGO (0.3 μM, 5min) application in saline (blue traces) and EtOH (red traces)-injected mice. b, c EtOH disrupted mOP-
LTD induced by DAMGO (0.3 μM, 5min) in the DLS (P= 0.0038, t9= 3.87, saline n= 6 from 3 mice and EtOH n= 5 from 2 mice). d Representative
electrically evoked synaptic traces from the DMS before and after DAMGO (0.3 μM, 5min) application in saline (blue traces) and EtOH (red traces)-
injected mice. e, f EtOH does not affect mOP-LTD induced by DAMGO (0.3 μM, 5min) in the DMS (P= 0.54, t12= 0.627, saline n= 7 from 3 mice and
EtOH n= 7 from 3 mice). Unpaired Student’s t test. **P < 0.01. Further statistical analysis shows a signiﬁcant interaction between exposure to in vivo EtOH
and subregion (P= 0.038, F(1, 21)= 4.9, two-way ANOVA). Data represent mean ± SEM
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natural reward control. A parallel cohort of mice was used to
estimate blood ethanol concentrations (BECs) to avoid stress
effects of blood sampling on mOP-LTD. Blood samples were not
collected from mice to be used in electrophysiology experiments
due to the concern that stress signiﬁcantly inﬂuences MSN
synaptic plasticity measurements37. EtOH consumption in mice
used in electrophysiology experiments was not different from this
parallel cohort (Supplementary Fig. 2a, b). EtOH consumption
was signiﬁcantly predictive of BECs as determined by a regression
analysis (Supplementary Fig. 2c, d). Using the obtained best-ﬁt
regression line, we predicted that the BECs of mice used in
electrophysiology experiments were likely between ~80 and 150
mg/dl on day 4 of DID given their measured EtOH intake
(Supplementary Fig. 2c, d). Altogether, we are conﬁdent that the
mice used in electrophysiology plasticity experiments consumed
physiologically relevant, binge-like levels of EtOH. Electro-
physiology experiments evaluated the effects of sucrose or EtOH
binge drinking on mOP-LTD in the DLS at increasing intervals
following the last drinking session. Given that EtOH had no effect
on DMS mOP-LTD (Fig. 3d–f), we focused the remainder of our
experiments on the DLS. We found that MSNs from sucrose-
drinking mice exhibited normal mOP-LTD 1 h following the last
DID session (73.3 ± 3.6%; Fig. 4d, f). mOP-LTD was also
apparent at 1 (75.8 ± 2.8%; Fig. 4e, f), 2 (65.3 ± 6.3%: Fig. 4f), 3
(71.1 ± 5.8%; Fig. 4f), and 4 (77.7 ± 9.1%) days following the ﬁnal
sucrose DID session. mOP-LTD in MSNs from EtOH-drinking
mice was disrupted 1 h after the ﬁnal day 4 DID session (90.1 ±
2.6%; Fig. 4d, f). Intriguingly, this disruption persisted for 1
(105.1 ± 5.0%; Fig. 4e,f), 2 (91.4 ± 3.2%; Fig. 4f), and 3 (92.6 ±
2.2%; Fig. 4f) days after the cessation of DID drinking. By day 4
however, mOP-LTD recovered to normal levels (78.1 ± 8.5%;
Fig. 4f). These results suggest that a single experimenter-
administered EtOH exposure and repeated binge-like EtOH
drinking can similarly disrupt MOR plasticity in the DLS. Given
that intake of the natural reward sucrose had no effect on mOP-
LTD, these observations cannot simply be due to the activation of
reward mechanisms. These observations are therefore EtOH
speciﬁc.
Effect of EtOH is speciﬁc to corticostriatal synapses. To further
characterize the synapse-speciﬁc effects of EtOH on MOR-
mediated plasticity in DLS, we probed the effect of a single in vivo
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Fig. 4 Voluntary binge EtOH drinking disrupts DLS mOP-LTD for several days. a Schematic ﬁgure summarizes the drinking in the dark (DID) paradigm. b, c
Graph showing DID consumption data (EtOH and sucrose intake) in C57BL/6J mice (n= 12 EtOH and n= 8 sucrose). d EtOH consumption prevented
mOP-LTD (0.3 μM DAMGO, 5min) at 1 h post binge drinking, while sucrose mice showed normal mOP-LTD (P= 0.0022, t12= 3.873; EtOH: n= 8 from 3
mice; Sucrose: n= 6 from 2 mice). e After 24 h of ending the DID procedure, EtOH mice show a lack of mOP-LTD in the DLS, but activation of MORs in
sucrose mice produces mOP-LTD (P= 0.0005, t10= 5.101; EtOH: n= 6 from 2 mice; sucrose: n= 6 from 2 mice). f EtOH disrupts mOP-LTD from d 1 h as
well as e 1 day, 2 days (P= 0.0014, t13= 4.05; EtOH: n= 9 from 3 mice; sucrose: n= 8 from 2 mice), and 3 days (P= 0.0024, t15= 3.646; EtOH: n= 9
from 3 mice; sucrose: n= 8 from 2 mice) after the cessation of DID drinking. At day 4 post DID, the activation of MORs by DAMGO in both EtOH and
sucrose mice induces equivalent mOP-LTD (P= 0.974, t6= 0.0342; EtOH: n= 4 from 1 mouse; Sucrose: n= 4 from 2 mice). Gray bars highlight the 4 h
DID session on day 4. Unpaired Student’s t test. **P < 0.01, ***P < 0.01. Data represent mean ± SEM
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EtOH exposure in Ai32-Emx1Cre+ and Ai32-Vglut2Cre+ mice.
We found that mOP-STD of thalamic inputs (Fig. 5a–c) is
unaffected by EtOH exposure at the peak inhibition (77.0 ± 6.9%
saline vs 76.5 ± 7.9% EtOH; Fig. 5c) and at 40–50 min (97.1 ±
7.9% saline vs 94.9 ± 5.7% EtOH; Fig. 5c). However, activation of
MORs on cortical inputs produced a stable LTD in saline-injected
mice (74.2 ± 7.7%; Fig. 5d–f) and a single EtOH injection was able
to disrupt this mOP-LTD 24 h later (106.5 ± 7.8%; Fig. 5d–f).
Finally, neither bath application of 20 (91.62 ± 4.0 %) or 40 mM
EtOH (93.5 ± 4.3 %) induced a synaptic depression of oEPSCs
nor blocked mOP-LTD in the DLS (20 mM: 66.4 ± 7.8 % and 40
mM: 67.7 ± 6.1 %; Supplementary Fig. 3). Furthermore, in vivo
EtOH exposure did not affect the stimulus intensity response of
eEPSCs (Supplementary Fig 4a, b), synaptic properties of spon-
taneous EPSCs (sEPSCs: Supplementary Fig. 5), or miniature
EPSCs (mEPSCs: Supplementary. 6) in the DLS. These observa-
tions indicate that EtOH does not appear to induce LTD on its
own and thus occludes ex vivo probing of mOP-LTD.
CINs are known to gate corticostriatal glutamatergic signal-
ing38–40 and are also reported to co-release glutamate9.
Furthermore, it has been shown that MORs regulate CIN
activity41,42. It is therefore possible that mOP-LTD could also
occur via MOR regulation of CIN activity. To test this, we
expressed Channelrhodopsin2 (ChR2) in dorsal striatal CINs in
ChATCre+ mice (Fig. 6a, b)43,44. We found that application of
DAMGO produced a persistent reduction in the magnitude of
oEPSCs recorded in MSNs produced by photostimulation of
CINs in the DLS of saline-injected mice (76.8 ± 4.2%). This novel
form of LTD, CIN-mOP-LTD, was equivalent in EtOH-injected
ChR2-expressing ChATCre+ mice (81.5 ± 3.8%; Fig. 6d, e). To
further characterize the glutamatergic CIN activity, we blocked
glutamate currents using the AMPA receptor antagonist, NBQX
(5 μM). NBQX was incapable of blocking the evoked current
entirely, suggesting that the remaining current (34.9 ± 10.5 %) is
likely due to nAChR activation (Supplementary Fig. 7a-c).
Interestingly, the application of the α7 antagonist methyllycaco-
nitine (MLA: 100 nM) did not affect the induction of mOP-LTD
by DAMGO (Supplementary Fig. 7d-f). Given that α7 nAChRs
selectively affect glutamate release from presynaptic corticostriatal
terminals40,45,46, these negative results suggest that CIN-mOP-
LTD measured in DLS MSNs is not a result of an indirect effect of
acetylcholine acting on MOR-expressing cortical terminals, but
rather occurs directly via a reduction in glutamate release from
the CINs onto MSNs. Finally, we used MOR-ﬂox/ChATCre+
mice injected with AAV9.DIO.ChR2 in DLS (Supplementary
Fig. 8a) to conﬁrm that MORs on CINs, themselves, are
responsible for this novel form of mOP-LTD. MOR-ﬂox/
ChATCre+ mice did not express CIN-mOP-LTD (97.9 ± 5.7 %;
Supplementary Fig. 8b-d). These data, along with our cortical and
thalamic input data, indicate that EtOH has a synapse-speciﬁc
effect rather than a MOR plasticity type-speciﬁc effect.
mOP-LTD speciﬁcally occurs at insular cortex inputs to DLS.
Our data to this point indicate that MOR activation is sufﬁcient
to induce EtOH-sensitive mOP-LTD at corticostriatal synapses.
To further establish the necessary role of MORs on cortical
terminals in mOP-LTD, we used conditional MOR knockout
mice (MOR-ﬂox/Emx1Cre+), lacking MORs exclusively on cor-
tical inputs (Fig. 7a, b). DAMGO application was incapable of
producing mOP-LTD of eEPSCs in MOR-ﬂox/Emx1Cre+ mice
(97.4 ± 3.1%; Fig. 7c) compared to wild-type MOR-ﬂox/Emx1cre-
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Fig. 5 A single in vivo exposure to ethanol disrupts mOP-LTD at cortical inputs but not mOP-STD at thalamic inputs. a Representative light-evoked synaptic
traces (oEPSC) from the DLS during baseline, immediately after DAMGO (0.3 μM, 5min) application (14–19 min), and ﬁnal 10min of recording in saline
(blue traces) and EtOH (red traces)-injected Ai32-Vglut2Cre+ mice. b, c EtOH does not affect peak inhibition (P= 0.96, t13= 0.05, saline n= 7 from 2
mice and EtOH n= 8 from 2 mice) or mOP-STD induced by DAMGO in the DLS (P= 0.824, t13= 0.227, saline n= 7 from 2 mice and EtOH n= 8 from 2
mice). d Representative oEPSC traces from DLS before and after DAMGO (0.3 μM, 5min) application in saline (blue traces) and EtOH (red traces)-
injected Ai32-Emx1Cre+ mice. e, f EtOH produces a disruption of mOP-LTD from cortical inputs induced by DAMGO (0.3 μM, 5min) in the DLS (P=
0.016, t14= 2.75, saline n= 6 from 2 mice and EtOH n= 10 from 4 mice). Unpaired Student’s t test. *P < 0.05. Data represent mean ± SEM
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counterparts (76.0 ± 4.4%; Fig. 7c). These data indicate that
MORs on cortical inputs are both necessary and sufﬁcient to
induce mOP-LTD of glutamatergic transmission within the DLS.
Having characterized and established the role of MORs on
corticostriatal inputs, we further attempted to determine the
speciﬁc cortical region involved in mOP-LTD. We infused AAV-
ChR2 vector into medial prefrontal (mPFC) and orbitofrontal
cortex (OFC) to evaluate the role MORs on those cortical inputs.
We found that glutamate release from both mPFC and OFC
inputs to DLS was unaffected by the activation of MORs
(Supplementary Fig. 9). Our prior work also determined that
motor cortex was not involved in the generation of mOP-LTD2. It
is therefore possible that mOP-LTD could occur in a non-
classical addiction-related cortical-DLS circuit. Another cortical
area with substantial input to DS is the anterior agranular insular
cortex11,47. We hypothesized a possible role of anterior insular
inputs to DLS MSNs in regulating mOP-LTD. To test this, we
expressed ChR2 in anterior insular cortex and recorded oEPSCs
in MSNs in the DLS (Fig. 8a). We noted that anterior insular
projections were mainly found in the DLS and nucleus
accumbens in our brain slices (Fig. 8a). DAMGO treatment was
indeed sufﬁcient to produce glutamatergic mOP-LTD of optically
stimulated anterior insular corticostriatal synapses (76.7 ± 5.2 %,
Fig. 8b, c). Furthermore, application of the MOR antagonist
CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) comple-
tely blocked the induction of mOP-LTD at these synapses (96.6 ±
5.8 %; Fig. 8c, d). These data suggest that MORs at anterior
insular cortex inputs to the DLS are capable of expressing mOP-
LTD in the DLS. Next, using i.p. EtOH injection (2.0 g/kg), we
evaluated whether anterior insular inputs are sensitive to in vivo
EtOH exposure. We found that EtOH was able to disrupt mOP-
LTD from anterior insular inputs 24 h post injection (72.9 ± 5.8%
saline vs 102.4 ± 5.0 % EtOH; Fig. 8e-g), similar to our earlier
observations reported in Figs. 3–5.
To further characterize this new role of anterior insular cortex
dorsal striatal inputs, we used MOR-ﬂox mice injected with
AAV-cre vector to knock out the expression of MORs speciﬁcally
in the anterior insular cortex (Fig. 9a). Using electrical
stimulation and recording in the DLS (Fig. 9a), we found that
DAMGO application did not produce mOP-LTD (93.6 ± 5.8%,
Fig. 9b), although a subsequent high-frequency stimulation (HFS)
train was able to induce eCB-LTD after application of DAMGO
(DAMGO: 89.1 ± 5.0%; HFS: 56.6 ± 10.2%, Fig. 9c, d). Finally,
MOR knockout from the anterior insular cortex leaves dOP-LTD
intact (Supplementary Fig. 10). Altogether, these data suggest that
MORs speciﬁcally on anterior insular cortex inputs are both
necessary and sufﬁcient to induce mOP-LTD in the DLS and are
uniquely affected by in vivo ethanol exposure.
Discussion
The current study conﬁrmed previously established mOP-LTD in
DLS2 (Fig. 1) and now demonstrates that it occurs in mouse DMS
as well (Fig. 1). MOR-mediated inhibition of glutamate release
could occur at three distinct synapse types in the DS: the gluta-
matergic inputs from cortex or thalamus, or driven by CIN
activation9. Using Cre-dependent ChR2-expressing transgenic
mice28,29, we determined that corticostriatal glutamatergic inputs
are involved in mOP-LTD, while thalamostriatal synapses
expressed mOP-STD (Fig. 2). Indeed, ablating MOR expression
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in corticostriatal synapses leads to a selective disruption of mOP-
LTD using electrical stimulation, suggesting that presynaptic
MORs are mediating this plasticity in the DS (Fig. 7). In addition,
we presented a novel characterization of mOP-LTD of direct CIN
glutamate release within the DLS (Fig. 6, Supplementary Fig. 7).
Activation of MORs located on CINs appear to be responsible for
this form of LTD (Supplementary Fig. 8).
Until now, the cortical region(s) that mediate mOP-LTD were
unknown. The DS receives major projections from many cortical
regions including, but not limited to, mPFC, OFC, and sensor-
imotor areas. Here we used optogenetic stimulation of mPFC and
OFC inputs to the DLS and established that presynaptic MOR
activation from those cortical terminals did not produce gluta-
matergic synaptic depression. Furthermore, our previous ﬁndings
indicate that motor cortex is also not involved in the induction of
mOP-LTD2. The lack of mOP-LTD, or even an acute response to
DAMGO, from these regions can be explained as a lack of MOR
availability to induce synaptic depression. Therefore, we related
our loss of mOP-LTD in MOR-ﬂox/Emx1Cre+ mice (Fig. 7) to
another cortical region. The speciﬁc optical stimulation of ante-
rior insular terminals and activation of presynaptic MORs leads
to synaptic plasticity that was blocked by the MOR antagonist
CTAP. In addition, the knockout of MORs from anterior insular
inputs completely abolished mOP-LTD in DLS, but not eCB-LTD
or dOP-LTD, indicating the speciﬁcity of this circuit for MOR-
mediated regulation of glutamate release. Our results demonstrate
that the anterior insular cortex-to-DLS input is the critical pro-
jection that expresses MOR-mediated long-term plasticity.
Alterations in the plasticity of this input to DLS suggest that this
circuit could mediate behaviors such as decision making48,
interoception49, pain50,51, taste learning behavior52,53, compulsive
alcohol use54, cocaine seeking and intake55,56, and opiate-related
positive and negative affective learning57. Thus, now that we
know the speciﬁc cortical input that is responsible for mOP-LTD
in the DLS, we can begin new efforts to interpret the behavioral
ramiﬁcations of our EtOH-mediated mOP-LTD disruption.
EtOH exposure-mediated disruption of mOP-LTD is con-
sistent with what we have previously shown for oxycodone
exposure2. Our ﬁndings show that both experimenter-
administered and voluntary binge-like EtOH exposure can
ablate long-term glutamatergic synaptic depression mediated by
the activation of MORs. Furthermore, the effect of voluntary
binge-like drinking on mOP-LTD persisted for 3 days following
the cessation of EtOH access. This EtOH-disrupted mOP-LTD
was similar to previous observations with i.p. oxycodone treat-
ment, an effect which also persisted for multiple days post
treatment2. Although mOP-LTD was not assessed 1 h post EtOH
injection in this study, we expect that mOP-LTD would be
similarly disrupted as was observed in the drinking experiment.
Our previous data show that i.p. oxycodone blocks the induction
of mOP-LTD 1 h after exposure2 and persists for 3 days. This is
very similar to the ﬁndings of the binge drinking experiment in
the current study. It is of great interest that the effects of EtOH
and oxycodone both persisted long after even limited exposure
had ceased. Future work will need to determine if a longer history
of EtOH drinking will produce more persistent effects (i.e.,
beyond 3 days) on plasticity as others have shown for
cocaine58,59.
Both oxycodone and EtOH exposure suppress eCB-LTD in the
DS, plasticity that also interacts with mOP-LTD2,13,15,17. CINs
are important components of corticostriatal eCB-LTD38, and
EtOH effects on dorsal striatal output have been proposed to
operate by affecting cholinergic signaling60. Therefore, consider-
ing the role of MORs in modulating CIN activity41,42, it was
important for us to address the possibility that the effects of EtOH
on mOP-LTD could be occurring as a result of altered CIN-
driven glutamate signaling. However, we found that our observed
EtOH effects were not related to altered CIN-mOP-LTD (Fig. 6).
These data further support that EtOH has synapse-speciﬁc effects,
rather than just plasticity type-speciﬁc effects. mOP-LTD in the
DMS and of CIN-driven glutamate release in DLS are both
unaffected by EtOH treatment, whereas mOP-LTD at corticos-
triatal DLS synapses is selectively disrupted. Speciﬁcally, having
demonstrated that the activation of anterior insular inputs onto
the DLS MSNs are necessary and sufﬁcient to induce mOP-LTD,
the ﬁnding that EtOH exposure disrupts the MOR-mediated LTD
occurring at this projection suggests that insular MORs may be
important targets of adaptation in EtOH-related behaviors. Pre-
vious studies have demonstrated a role for MORs in mediating
responding for natural rewards18, but our data here demonstrate
that sucrose has no effect on mOP-LTD (Fig. 4). Thus, insular
cortex-DLS mOP-LTD may therefore be particularly sensitive to
drugs of abuse.
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The selective effects of EtOH on dorsal striatal subregion (DLS,
not DMS), type of plasticity (LTD, not STD), and synapse type
(insular corticostriatal, not thalamostriatal or cholinergic) provide
some interesting possibilities for how EtOH may inﬂuence
behavior in that it spares opioid signaling at some dorsal striatal
synapses, while weakening it at others. Speciﬁc EtOH effects
could be due to the different innervations that each dorsal striatal
subregion receives10 (insular inputs reach mainly DLS, Fig. 8a),
resulting in different synaptic environments. As such, this may
explain differences in their sensitivity to EtOH. The lack of a
statistical difference between subregions in mOP-LTD magnitude
(Fig. 3) also suggests that no pre-existing differences in the
relative strengths of mOP-LTD in DMS versus DLS could have
precluded the potential to observe an EtOH effect in the DMS.
It has been proposed that addiction-related dorsal striatal
neuroadaptations facilitate the development of habit learning in
the context of substance-related behavior61. The speciﬁcity and
duration of our observed EtOH effect (3 days post drinking) has
signiﬁcant implications for how acute EtOH exposure produces
functional changes selectively within the DLS, a brain region
known to promote habitual EtOH seeking14. Opioid signaling has
also been implicated in habit learning62 and is clearly involved in
Control CTAP block
0
25
50
75
100
125
*
+2.4
+1.2
AAV.hSyn.ChR2.YFP
C57 mice
oE
P
S
C
 (
%
 b
as
el
in
e)
DAMGO
CTAP
100 pA
50 ms
CTAP block
100 pA
50 ms
Control
DAMGO
Saline
Saline
EtOH
EtOH
0
25
50
75
100
125 **
200 pA
50 ms
ba
dc
0 5 10 15 20 25 30 35 40 45 50
Time (min)
0 5 10 15 20 25 30 35 40 45 50
Control
CTAP block
Time (min)
125
100
75
50
25
0
125
100
75
50
25
0
oE
P
S
C
 (
%
 b
as
el
in
e)
oE
P
S
C
 (
%
 b
as
el
in
e)
oE
P
S
C
 (
%
 b
as
el
in
e)
e f g
Fig. 8 mOP-LTD occurs at anterior insular cortex inputs to DLS and is ethanol sensitive. a Schematic ﬁgure of the injection paradigm enabling optogenetic
recording from C57BL/6J DLS MSNs. An AAV vector coding for ChR2 (AAV.hSyn.ChR2) was injected 14 days prior to recordings. Coronal brain slices
showing the infection of anterior insular cortex sending projections to the DLS and nucleus accumbens. Bar scales: +2.4, 200 μm; +1.7, 1000 μm; +1.2,
1000 μm; +0.1, 1000 μm. b Representative light-evoked synaptic traces from the DLS before and after DAMGO (0.3 μM, 5min) and blocked with MOR
antagonist CTAP (1 μM). c, d DAMGO application induced mOP-LTD at anterior insular terminals in the DLS and this MOR-mediated LTD was blocked by
the application of CTAP (P= 0.027, t13= 2.49, Control: n= 9 from 3 mice; CTAP: n= 6 from 2 mice). e Representative oEPSC traces from the DLS before
and after DAMGO (0.3 μM, 5min) application in saline (blue traces) and EtOH (red traces)-injected C57BL/6J mice. f, g EtOH exposure produced a
disruption of mOP-LTD from anterior insular inputs induced by DAMGO (0.3 μM, 5min) in the DLS (P= 0.0046, t9= 3.75; Saline: n= 6 from 2 mice;
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NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03683-1 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1318 | DOI: 10.1038/s41467-018-03683-1 | www.nature.com/naturecommunications 9
behavioral responding for alcohol18. Alternatively, data have also
demonstrated that MOR activation in the DLS of rats signiﬁcantly
enhances the incentive salience of reward-associated cues63. This
enhancement essentially manifests as the cue(s) itself serving as a
primary reward. Individuals with substance use disorders may
more strongly seek these cues over time, thus increasing craving
and the likelihood of consumption64,65. The extent of such EtOH-
induced functional adaptations in the DLS opioid signaling may
therefore be important for an individual’s risk for developing an
AUD. The observation that MORs are important regulators of
EtOH conditioned place preference66 and locomotor sensitiza-
tion67, behaviors that develop over time with repeated exposure,
suggests that these behavioral changes are likely accompanied by
alterations in synaptic plasticity. During the pre-dependent stage
of alcohol exposure, changes in the functional dynamics of pre-
synaptic DLS MOR signaling could occur, perhaps reﬂecting a
critical transition state to problematic alcohol use as has been
demonstrated in opiate-related positive and negative affective
learning governed by the insular cortex57. This hypothesis
appears to be consistent with our ﬁnding that EtOH exposure
interrupts the functional ability of the MOR to suppress gluta-
matergic drive in the DLS. Others have utilized the DID model to
determine if EtOH exposure produces changes in basal
glutamatergic signaling, but did not ﬁnd any effect68. Our data
support these ﬁndings as well (Supplementary Figs. 3-6). This
suggests that EtOH is not preventing mOP-LTD expression in
slice by occlusion, but rather is preventing its induction. Addi-
tional work is needed to determine the molecular mechanisms
underlying this disruption. Identifying these mechanisms may
allow for the discovery of pharmacological targets as intervention
strategies for the excessive incentive salience and/or habitual
component(s) of AUDs.
Finally, an important question for these experiments is whether
stress inﬂuenced mOP-LTD measurements. Indeed, stressors can
disrupt synaptic plasticity in MSNs37. As mice received i.p.
injections or underwent surgery in some of our experiments, this
is an important consideration. In addition, mice could have been
in a dysphoric state of EtOH withdrawal in some experiments. In
our case, we performed some experiments with saline-injected
controls. Comparatively, mOP-LTD data from these animals are
highly similar to naive animals (Figs. 1 and 3). In addition, the
DMS data in Fig. 3 indicate that EtOH-injected mice show no
effect of EtOH exposure on mOP-LTD. As this was 24 h later, any
sort of withdrawal state that may interfere with plasticity would
be present, but no effect was found. Furthermore, in our
experiment with MOR-ﬂox/Emx1Cre mice (Fig. 7c), animals
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recording time course from the DLS before and after DAMGO (0.3 μM, 5min) and high-frequency stimulation (HFS) coupled with depolarization (4 pulses
of 100 Hz, 10 s inter-pulse interval). DAMGO application was incapable of producing mOP-LTD in the DLS of anterior insula MOR knockout mice. However,
HFS induced a strong reduction of eEPSCs in the DLS, indicating intact eCB-LTD (baseline vs DAMGO: P= 0.262, t3= 1.3.78; baseline vs HFS: P= 0.0082,
t3= 6.259; DAMGO vs HFS: P= 0.0467, t3= 3.273; n= 4 from 3 mice). Data analyzed with Student’s paired t tests. Data represent mean ± SEM
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03683-1
10 NATURE COMMUNICATIONS |  (2018) 9:1318 | DOI: 10.1038/s41467-018-03683-1 | www.nature.com/naturecommunications
were not injected and mOP-LTD was blocked by the knockdown
of MOR from the cortex in the absence of any stressors. We
therefore believe that the possibility that stress could have been
responsible for or contributed to any of our plasticity measure-
ments is unlikely.
In conclusion, our data provide the ﬁrst evidence that MORs
produce different types of synaptic plasticity at distinct dorsal
striatal glutamatergic synapses and that EtOH has persistent, yet
selective, effects on this plasticity. We found that mOP-LTD in
the DLS was speciﬁcally expressed at anterior insular cortex
inputs and EtOH affects this plasticity in a unique manner. How
mOP-LTD at insular synapses may be involved in DS-dependent
behaviors and how this relates to EtOH effects on the expression
of these behaviors will be of interest in our future investigations.
Methods
Animals and materials. Animal care and experimental protocols for this study
were approved by the Institutional Animal Care and Use Committee at the Indiana
University School of Medicine and all guidelines for ethical protocols and care of
experimental animals established by the NIH (National Institutes of Health,
Maryland, USA) were followed. Male C57BL/6J mice were ordered from the
Jackson Laboratory (Bar Harbor, Maine, USA). Ai32-Emx1Cre, Ai32-Vglut2Cre,
and ChATCre transgenic mice were bred and genotyped in-house (Original stock
strains: Ai32: JAX #012569; ChATCre: JAX #006410; Emx1Cre: JAX #005628;
Vglut2Cre: JAX #016963). Conditional MOR knockout mice (MOR-ﬂox) were a
generous gift from Dr. Jennifer Whistler (UCSF)69. All transgenic mice used in
these studies have been backcrossed to C57BL/6J mice for a minimum of 7 gen-
erations. MOR-ﬂox mice were crossed with Emx1Cre mice to produce cortical
projection neuron MOR knockout mice (MOR-ﬂox/Emx1Cre) and crossed with
ChATCre mice to produce MOR knockout from CINs. The mice used in these
studies were between postnatal day (PND) 32 and 90 at the time of experi-
mentation (with the exception of ChATCre mice that were ~PND 60–150 and
MOR-ﬂox AAV-cre-injected mice ~PND 116–136), with all mice involved in the
drinking studies between PND 70 and 80. Animals were group-housed (with the
exception of the voluntary drinking experiment outlined below) in a standard 12 h
light/dark cycle (lights on at 0800 h). Humidity in the viviarium was held constant
at 50% and food and water were available ad libitum, except where noted other-
wise. Drugs and reagents were purchased from Fisher Scientiﬁc, Tocris, Sigma-
Aldrich, or Bachem Americas.
Brain slice preparation. Immediately following killing via decapitation under deep
isoﬂurane anesthesia, the brain was quickly excised and placed in an ice-cold
cutting solution containing (in mM): 194 sucrose, 30 NaCl, 4.5 KCl, 1 MgCl2, 26
NaHCO3, 1.2 NaH2PO4, 10 Glucose saturated with a mixture of 95% O2 and 5%
CO2, and sliced to a thickness of 280 μm on a vibratome (Leica VT1200S, Ger-
many). Slices were transferred to an artiﬁcial cerebrospinal ﬂuid (aCSF) solution
containing (in mM): 124 NaCl, 4.5 KCl, 1 MgCl2, 26 NaHCO3, 1.2 NaH2PO4, 10
Glucose, 2 CaCl2 (310–320 mOsm) saturated with 95% O2/5% CO2 at 30 °C for 1 h
before being moved to room temperature. When ready for recording, slices were
transferred to a recording chamber continuously perfused with aCSF solution
saturated with 95% O2/5% CO2.
Electrophysiology recordings. Whole-cell, voltage-clamp recordings of EPSCs
from MSNs were carried out at 29–32 C° and aCSF was continuously perfused at a
rate of 1–2 ml/min. Whole-cell patch clamp recordings in the voltage-clamp
conﬁguration were made from MSNs using a Multiclamp 700B ampliﬁer (Axon
Instruments, Union City, CA). Slices were visualized on an Olympus BX51WI
microscope (Olympus Corporation of America). MSNs were identiﬁed by their
size, membrane resistance, and capacitance. Picrotoxin (50 μM) was added to the
aCSF for recordings to isolate excitatory transmission. Patch pipettes were prepared
from ﬁlament-containing borosilicate micropipettes (World Precision Instruments)
using a P-1000 micropipette puller (Sutter Instruments, Novato, CA), having a
2.0–3.5 MΩ resistance. The internal solution contained (in mM) 120 CsMeSO3, 5
NaCl, 10 TEA-Cl, 10 HEPES, 5 lidocaine bromide, 1.1 EGTA, 0.3 Na-GTP, and 4
Mg-ATP (pH 7.2 and 290–310 mOsm). MSNs were voltage clamped at −60 mV
for the duration of the recordings. For DLS recordings, a tungsten bipolar sti-
mulating electrode (PlasticsONE, Roanoke, VA) was placed at the border of the
white matter of the external capsule. For DMS recordings, the stimulating electrode
was placed at the border of the overlying corpus callosum. eEPSCs were generated
by a DS3 Isolated Current Stimulator (Digitimer, Ft. Lauderdale, FL) every 20 s and
stimulus intensity was adjusted to produce stable eEPSCs of 200–400 pA in
amplitude prior to the initiation of experimental recording. Data were acquired
using Clampex 10.3 (Molecular Devices, Sunnyvale, CA). Series resistance was
monitored and only cells with a stable series resistance (less than 25MΩ and that
did not change more than 15% during recording) were included for data analysis.
Recordings were made 2–7 h after killing. The experimenter was not blinded to
treatments administered to the mice.
Experimenter-administered EtOH exposure. Mice (PND 28–42) received i.p.
injections of 0.9% NaCl saline or 2 g/kg EtOH. At 24 h after injection, mice were
killed and brain slices were obtained for electrophysiological recordings (as
described above). Mice were randomly selected for injection type.
Drinking-in-the-dark model. The DID model is a simple drinking paradigm that
requires no previous training or ﬂuid restriction35. Brieﬂy, mice were offered
limited access (2–4 h) to EtOH (20% v/v in water) or sucrose (2% w/v in water) via
modiﬁed double ball bearing sipper tubes. Mice were randomly assigned to each
ﬂuid group. Common utilization of this model is to offer 3 days of 2 h access to
these solutions, with a 4 h session on day 4 to provide an opportunity for greater
consumption35. Mice had ad libitum access to their standard water bottles at all
other times. Given that natural rewards (e.g., sugar, sex, etc.) can also involve
classical reward circuitry which has been studied in drug and alcohol research70,
sucrose was used in the current study as an alternative reinforcer comparison.
Historically, 20% EtOH consumption via DID produces signiﬁcant behavioral
intoxication and blood EtOH concentrations in excess of 100 mg/dl35. Given that
EtOH consumption occurs within this discrete period of time (2–4 h), DID is often
referenced as a ‘binge-like’ drinking model.
In a subset of mice not included in electrophysiological experiments, retro-
orbital blood samples were taken after the ﬁnal DID drinking period and BECs
were determined via gas chromatography (Shimadzu GC-2010 plus).
Viral injections. Male ChATCre+ and MOR-ﬂox/ChATCre+ mice were anes-
thetized with isoﬂurane and stereotaxically injected with the adeno-associated viral
(AAV) vector, AAV9.EF1a.DIO.ChR2(H134R)-YFP (Penn Vector Core), to drive
the photosentive cation channel, ChR2, expression solely in CINs. Bilateral injec-
tions were made into the DS at coordinates anteroposterior (A/P): +0.7, medio-
lateral (M/L): ±1.5, dorsoventral (D/V): −3.1 (100 nl/injection, 25 nl/min infusion
rate). Mice were allowed to recover for at least 2 weeks before brain slices were
made for electrophysiological recordings. Male C57BL/6J mice were anesthetized
with isoﬂurane and stereotaxically injected with the AAV vector, AAV9.hSyn.ChR2
(H134R)-eYFP (Penn Vector Core), to drive ChR2 expression in mPFC, OFC, and
anterior insular neurons. Bilateral injections were made into mPFC at coordinates
A/P: +1.9, M/L: ±0.3, D/V: −2.3 (100 nl/injection, 25 nl/min infusion rate); OFC:
A/P: +2.7, M/L: ±1.75, D/V: −2.25 (100 nl/injection, 25 nl/min infusion rate); and
anterior insular cortex: A/P: +2.4, M/L: ±2.2, D/V: −2.25 (50 nl/injection, 12.5 nl/
min infusion rate).
To produce anterior insular cortical projection neuron MOR knockout mice,
MOR-ﬂox mice were anesthetized with isoﬂurane and stereotaxically injected with
AAV9.hSyn.Cre.YFP (Penn Vector Core). Bilateral injections were made into
anterior insular cortex at coordinates A/P: +2.4, M/L: ±2.2, D/V: −2.25 (50 nl/
injection, 12.5 nl/min infusion rate). MOR-ﬂox mice were allowed to recover for at
least 8 weeks to allow for adequate ablation of MOR expression before brain slices
were made for electrophysiological recordings.
Optogenetic recordings. Ai32-Emx1Cre and Ai32-Vglut2Cre transgenic mice
congenitally express ChR2 on cortical and thalamic projection neurons, respec-
tively28,29. AAV-ChR2-injection in ChATCre and MOR-ﬂox/ChATCre mice
allows for targeted recombination manipulations only within CINs43,44. They were
used in the present study to express ChR2 into dorsal striatal CINs. AAV-ChR2
injection in C57BL/6J mice was performed to target ChR2 expression on inputs
from mPFC, OFC, and anterior insular cortex to DLS. oEPSCs in MSNs were
evoked in brain slices using 470 nm blue light (5 ms exposure time) delivered via
ﬁeld illumination through the microscope objective. Light intensity was adjusted to
produce stable oEPSCs of 200–400 pA amplitude prior to experimental recording
in Ai32 mice. In ChATcre mice, oEPSC amplitudes were generally much smaller,
even with maximal light stimulation. In these recordings oEPSC amplitudes ranged
from ~20 pA to 300 pA. oEPSCs were evoked once per min (AAV injected mice) or
every 30 s (Ai32-Emx1Cre, Ai32-Vglut2Cre, and C57BL/6J). Prior to recording,
brain slices were imaged via an Olympus MVX10 microscope (Olympus Cor-
poration of America) to verify YFP-tagged ChR2 expression in injected ChATCre
+, MOR-ﬂox/ChATCre, and C57BL/6J mice or properly localized ChR2 expression
(indicated by GFP ﬂuorescence) in Ai32-Emx1Cre and Ai32-Vglut2Cre mice.
Quantitative polymerase chain reaction. Prefrontal cortex (including medial
prefrontal, orbitofrontal, and anterior insular cortices) and thalamus tissue were
taken from MOR-ﬂox/Emx1cre (+) and MOR-ﬂox/Emx1cre (−) mice. RNA was
isolated from brain tissue using the RNeasy Plus Universal Mini Kit (Qiagen
#73404) according to the manufacturer’s protocol. Total RNA (50 ng/µl) was
converted to complementary DNA (cDNA) using the High Capacity cDNA
Reverse Transcription kit (Applied Biosystems Inc. (ABI), Foster City, CA:
4368814) and ampliﬁed using a TaqMan QuantStudio 6 Flex Real-Time PCR
System. The TaqMan probe used in the current study was Oprm1 (Assay ID:
Mm01188089_m1, Catalog #4331182, ThermoFisher). Quantitative PCR was
performed using TaqMan Gene Expression Master Mix reagents (Applied
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03683-1 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1318 | DOI: 10.1038/s41467-018-03683-1 | www.nature.com/naturecommunications 11
Biosystems). The relative amount of each transcript was determined via normal-
ization across all samples to the endogenous control GAPDH (TaqMan Rodent
GAPDH Control Reagents, Catalog #4308313) to account for variability in the
initial concentration and quality of the total RNA and in the conversion efﬁciency
of the reverse transcription reaction as recommended by ABI. In addition, before
initiation of the analysis, cDNA was diluted 1:50 and ampliﬁed using the respective
TaqMan probes to ensure that the amount of cDNA used was in the linear range.
RNA samples from each individual animal were run in triplicate.
To quantify the relative expression levels of the different genes for each mouse
genotype, we calculated the difference (ΔCt) between the cycle threshold of Oprm1
and the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
From these data, the ΔΔCt ([ΔCtOprm1(Cre+)–ΔCtOprm1(Cre-)]) was computed
and converted to a relative quantitative (RQ) value using the formula 2−ΔΔCt. The
results were tabulated as mean ± SEM and compared between genotypes via
unpaired Student’s t tests.
Reagents. The MOR agonist DAMGO (H-2535, Bachem), MOR antagonist CTAP
(H-3698, Bachem), delta opioid receptor agonist [D-Pen2,D-Pen5]-enkephalin
(DPDPE; H-2905m, Bachem), α7 nicotinic acetylcholine receptor antagonist
methyllycaconitine citrate (MLA; 1029, Tocris), AMPA antagonist NBQX (0373,
Tocris), tetrodotoxin citrate (ARCD-0640, ARC Inc.), EtOH (E7148, Sigma-
Aldrich), and GABAA receptor antagonist picrotoxin (P1675, Sigma-Aldrich) were
used.
Sample size. The target number of samples in each group for our electro-
physiological experiments was determined based on ﬁndings reported in our
previously published studies2. Using these effect sizes and an α-level set at 0.05 and
at 80% power, we determined that 5–7 electrophysiological recordings from at least
2 mice was an appropriate sample size. We did not use a speciﬁc methodology for
determining sample size for the qPCR analysis, but due to technical constraints
determined a priori that three biological replicates would be performed.
Replication. All sample sizes indicated in ﬁgures for behavioral and electro-
physiological experiments represent biological replicates. N equals the number of
slices recorded. The qPCR data are biological replicates.
Data analyses. Unless otherwise indicated, data were presented as the mean ±
SEM. The analyses of normally distributed data were performed using two-tailed
unpaired, two-tailed paired Student’s t tests following an F-test to conﬁrm similar
variances. Non-normally distributed data were analyzed using two-tailed Wilcoxon
matched-pairs signed rank tests for paired data. Data that were analyzed using this
test are indicated in the ﬁgure legends. Two-way analysis of variance (ANOVA) or
linear regression were performed in Fig. 3 and supplementary Figure 2, respec-
tively, and these data were not tested for normality. Statistical analyses were per-
formed with Prism 7 (GraphPad, La Jolla, CA). The level of signiﬁcance was set at
P < 0.05 for all analyses. Representative traces are the average baseline EPSC (1–10
min) and average post-treatment EPSC of ﬁnal 10 min of recording, unless
otherwise indicated. Exclusion of individual data points was determined using an
outlier calculator included in the Prism 7 software package.
Data availability. All data are available from the authors upon reasonable request.
Received: 12 October 2017 Accepted: 2 March 2018
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